A Case of Therapy-Related Acute Myeloid Leukemia Associated with Adjuvant Temozolomide Chemotherapy for Anaplastic Astrocytoma

Kenzo Kosugi, Katsuya Saito, Wataru Takahashi, Yukina Tokuda, Hideyuki Tomita

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background Temozolomide (TMZ) is now standard adjuvant therapy in combination with radiotherapy for patients with newly diagnosed malignant glioma. Treatment-related myelodysplastic syndrome and acute treatment-related leukemia (t-AML) associated with TMZ chemotherapy for patients with glioma is quite a rare complication. Case Description A 43-year-old man with an anaplastic astrocytoma received radiation therapy synchronized with ranimustine and adjuvant TMZ chemotherapy for 15 cycles. Close follow-up magnetic resonance imaging of the head during TMZ chemotherapy showed no evidence of tumor progression. One year after the completion of TMZ chemotherapy, a bone-marrow aspiration was performed because the patient's white blood cell count decreased. He was diagnosed with t-AML based on the bone marrow examination, and then he was referred to the cancer center for the treatment of t-AML. Conclusions In this case study, we continued adjuvant TMZ therapy beyond the recommended 6 cycles. Currently, there is no consensus as to how long the adjuvant TMZ therapy should be continued for the treatment of residual tumor showing no apparent interval change. A new decision-making tool to assess the clinical benefits against the side effects for long-term adjuvant TMZ therapy is needed.

Original languageEnglish
Pages (from-to)816.e11-816.e16
JournalWorld Neurosurgery
Volume101
DOIs
Publication statusPublished - 2017 May 1
Externally publishedYes

Fingerprint

temozolomide
Astrocytoma
Adjuvant Chemotherapy
Acute Myeloid Leukemia
Therapeutics
Leukemia
Drug Therapy
Glioma
Radiotherapy
Bone Marrow Examination

Keywords

  • Adjuvant temozolomide chemotherapy
  • Alkylating agents
  • Glioma
  • Therapy-related myelodysplastic syndrome/acute myeloid leukemia

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

A Case of Therapy-Related Acute Myeloid Leukemia Associated with Adjuvant Temozolomide Chemotherapy for Anaplastic Astrocytoma. / Kosugi, Kenzo; Saito, Katsuya; Takahashi, Wataru; Tokuda, Yukina; Tomita, Hideyuki.

In: World Neurosurgery, Vol. 101, 01.05.2017, p. 816.e11-816.e16.

Research output: Contribution to journalArticle

Kosugi, Kenzo ; Saito, Katsuya ; Takahashi, Wataru ; Tokuda, Yukina ; Tomita, Hideyuki. / A Case of Therapy-Related Acute Myeloid Leukemia Associated with Adjuvant Temozolomide Chemotherapy for Anaplastic Astrocytoma. In: World Neurosurgery. 2017 ; Vol. 101. pp. 816.e11-816.e16.
@article{6a3d5253e99f4eac979ae0f636d433c9,
title = "A Case of Therapy-Related Acute Myeloid Leukemia Associated with Adjuvant Temozolomide Chemotherapy for Anaplastic Astrocytoma",
abstract = "Background Temozolomide (TMZ) is now standard adjuvant therapy in combination with radiotherapy for patients with newly diagnosed malignant glioma. Treatment-related myelodysplastic syndrome and acute treatment-related leukemia (t-AML) associated with TMZ chemotherapy for patients with glioma is quite a rare complication. Case Description A 43-year-old man with an anaplastic astrocytoma received radiation therapy synchronized with ranimustine and adjuvant TMZ chemotherapy for 15 cycles. Close follow-up magnetic resonance imaging of the head during TMZ chemotherapy showed no evidence of tumor progression. One year after the completion of TMZ chemotherapy, a bone-marrow aspiration was performed because the patient's white blood cell count decreased. He was diagnosed with t-AML based on the bone marrow examination, and then he was referred to the cancer center for the treatment of t-AML. Conclusions In this case study, we continued adjuvant TMZ therapy beyond the recommended 6 cycles. Currently, there is no consensus as to how long the adjuvant TMZ therapy should be continued for the treatment of residual tumor showing no apparent interval change. A new decision-making tool to assess the clinical benefits against the side effects for long-term adjuvant TMZ therapy is needed.",
keywords = "Adjuvant temozolomide chemotherapy, Alkylating agents, Glioma, Therapy-related myelodysplastic syndrome/acute myeloid leukemia",
author = "Kenzo Kosugi and Katsuya Saito and Wataru Takahashi and Yukina Tokuda and Hideyuki Tomita",
year = "2017",
month = "5",
day = "1",
doi = "10.1016/j.wneu.2017.02.068",
language = "English",
volume = "101",
pages = "816.e11--816.e16",
journal = "World Neurosurgery",
issn = "1878-8750",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - A Case of Therapy-Related Acute Myeloid Leukemia Associated with Adjuvant Temozolomide Chemotherapy for Anaplastic Astrocytoma

AU - Kosugi, Kenzo

AU - Saito, Katsuya

AU - Takahashi, Wataru

AU - Tokuda, Yukina

AU - Tomita, Hideyuki

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Background Temozolomide (TMZ) is now standard adjuvant therapy in combination with radiotherapy for patients with newly diagnosed malignant glioma. Treatment-related myelodysplastic syndrome and acute treatment-related leukemia (t-AML) associated with TMZ chemotherapy for patients with glioma is quite a rare complication. Case Description A 43-year-old man with an anaplastic astrocytoma received radiation therapy synchronized with ranimustine and adjuvant TMZ chemotherapy for 15 cycles. Close follow-up magnetic resonance imaging of the head during TMZ chemotherapy showed no evidence of tumor progression. One year after the completion of TMZ chemotherapy, a bone-marrow aspiration was performed because the patient's white blood cell count decreased. He was diagnosed with t-AML based on the bone marrow examination, and then he was referred to the cancer center for the treatment of t-AML. Conclusions In this case study, we continued adjuvant TMZ therapy beyond the recommended 6 cycles. Currently, there is no consensus as to how long the adjuvant TMZ therapy should be continued for the treatment of residual tumor showing no apparent interval change. A new decision-making tool to assess the clinical benefits against the side effects for long-term adjuvant TMZ therapy is needed.

AB - Background Temozolomide (TMZ) is now standard adjuvant therapy in combination with radiotherapy for patients with newly diagnosed malignant glioma. Treatment-related myelodysplastic syndrome and acute treatment-related leukemia (t-AML) associated with TMZ chemotherapy for patients with glioma is quite a rare complication. Case Description A 43-year-old man with an anaplastic astrocytoma received radiation therapy synchronized with ranimustine and adjuvant TMZ chemotherapy for 15 cycles. Close follow-up magnetic resonance imaging of the head during TMZ chemotherapy showed no evidence of tumor progression. One year after the completion of TMZ chemotherapy, a bone-marrow aspiration was performed because the patient's white blood cell count decreased. He was diagnosed with t-AML based on the bone marrow examination, and then he was referred to the cancer center for the treatment of t-AML. Conclusions In this case study, we continued adjuvant TMZ therapy beyond the recommended 6 cycles. Currently, there is no consensus as to how long the adjuvant TMZ therapy should be continued for the treatment of residual tumor showing no apparent interval change. A new decision-making tool to assess the clinical benefits against the side effects for long-term adjuvant TMZ therapy is needed.

KW - Adjuvant temozolomide chemotherapy

KW - Alkylating agents

KW - Glioma

KW - Therapy-related myelodysplastic syndrome/acute myeloid leukemia

UR - http://www.scopus.com/inward/record.url?scp=85016506685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016506685&partnerID=8YFLogxK

U2 - 10.1016/j.wneu.2017.02.068

DO - 10.1016/j.wneu.2017.02.068

M3 - Article

C2 - 28288919

AN - SCOPUS:85016506685

VL - 101

SP - 816.e11-816.e16

JO - World Neurosurgery

JF - World Neurosurgery

SN - 1878-8750

ER -